Refers to the rapid progression of disease after immunotherapy during anti-PD-1/PD-L1 treatment.
A process describing tumor growth that violently speeds up as a result of treatment with immune checkpoint inhibitor therapy.
Hyperprogressive disease is defined as unexpected acceleration of tumor kinetics that can be measured on imaging with dynamic dynamic parameters.
Seen in as many as 4-29% of cases of cancer treated with immune drugs.
Patients with MDM2 amplifications or epidermal growth factor receptive mutations are associated with hyperprogression.